Latest Regulus Therapeutics Inc. Stories
LA JOLLA, Calif., June 11, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has named Stelios Papadopoulos, Ph.D. as Chairman of its Board of Directors effective immediately. Dr. Papadopoulos assumes the role of Chairman of the Board from John Maraganore, Ph.D., who will remain a member of the Board of Directors. Dr. Papadopoulos, who...
LA JOLLA, Calif., May 21, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the Deutsche Bank 38th Annual Healthcare Conference on Wednesday, May 29, 2013 at 3:30 pm EDT. The conference is being held at the Westin Boston...
LA JOLLA, Calif., May 7, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended March 31, 2013 on Tuesday, May 14, 2013, after the U.S. financial markets close. Regulus will host a conference call and webcast on Tuesday, May 14, 2013 at 5:00 pm Eastern Daylight Time to discuss its...
LA JOLLA, Calif., April 24, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer, will present a company overview at the 12(th) Annual Needham Healthcare Conference on Wednesday, May 1, 2013 at 12:10 pm EDT. The conference is being held at the Westin Grand Central Hotel in...
LA JOLLA, Calif., March 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the 20(th) Annual Future Leaders in the Biotech Industry Conference on Friday, April 5, 2013 at 10:30 am EDT. The conference is being held at...
LA JOLLA, Calif., Feb. 26, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the Cowen and Company 33rd Annual Healthcare Conference on Tuesday, March 5, 2013 at 8:40 am EST. The conference is being held at the Boston...
LA JOLLA, Calif., Feb. 20, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported its financial results for the fourth quarter and year-ended December 31, 2012 and recent company highlights. "In 2012, we successfully achieved significant strategic and financial objectives that have enabled Regulus to become a publicly-traded biopharmaceutical...
LA JOLLA, Calif., Feb. 13, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the fourth quarter and year ended December 31, 2012 on Wednesday, February 20, 2013, after the U.S. financial markets close. Regulus will host a conference call and webcast on Wednesday, February 20, 2013 at 5:00...
LA JOLLA, Calif., Feb. 4, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus, will present a company overview at the 15(th) Annual BIO CEO & Investor Conference on Tuesday, February 12, 2013 at 1:00 pm EST. Dr. Xanthopoulos will also present at the Leerink Swann Global...
LA JOLLA, Calif., Jan. 31, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the appointment of Mark G. Foletta to its Board of Directors and Audit Committee, effective immediately. "We are very pleased to have Mark join our Board," said John Maraganore, Ph.D., Chairman of the Board of Directors of Regulus and CEO of Alnylam...
